Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleHot Topics

Exploiting the Full Potential of β-Amyloid and Tau PET Imaging for Drug Efficacy Testing

Henryk Barthel, John Seibyl, Adriaan A. Lammertsma, Victor L. Villemagne and Osama Sabri
Journal of Nuclear Medicine August 2020, 61 (8) 1105-1106; DOI: https://doi.org/10.2967/jnumed.119.228346
Henryk Barthel
1Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Seibyl
2Institute for Neurodegenerative Disorders, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adriaan A. Lammertsma
3Department of Radiology and Nuclear Medicine, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor L. Villemagne
4Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia; and
5Department of Medicine, University of Melbourne, Heidelberg, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Osama Sabri
1Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Example of so-called coffee break or dual–time-window imaging protocol, in this case for 18F-florbetaben amyloid PET scan (6). Gray-shadowed time windows represent significantly shortened (as compared with full dynamic imaging) scan times for patients, whereas data in in-between interval are interpolated. This protocol increases patient compliance while still providing full-quality quantitative data. It even allows for high patient throughput via interleaved patient scheduling on PET scanner.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (8)
Journal of Nuclear Medicine
Vol. 61, Issue 8
August 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Exploiting the Full Potential of β-Amyloid and Tau PET Imaging for Drug Efficacy Testing
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Exploiting the Full Potential of β-Amyloid and Tau PET Imaging for Drug Efficacy Testing
Henryk Barthel, John Seibyl, Adriaan A. Lammertsma, Victor L. Villemagne, Osama Sabri
Journal of Nuclear Medicine Aug 2020, 61 (8) 1105-1106; DOI: 10.2967/jnumed.119.228346

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Exploiting the Full Potential of β-Amyloid and Tau PET Imaging for Drug Efficacy Testing
Henryk Barthel, John Seibyl, Adriaan A. Lammertsma, Victor L. Villemagne, Osama Sabri
Journal of Nuclear Medicine Aug 2020, 61 (8) 1105-1106; DOI: 10.2967/jnumed.119.228346
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders
  • {alpha}-Synuclein PET and Parkinson Disease Therapeutic Trials: Ever the Twain Shall Meet?
  • First Tau PET Tracer Approved: Toward Accurate In Vivo Diagnosis of Alzheimer Disease
  • Google Scholar

More in this TOC Section

  • Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature?
  • RECIP 1.0: A Roadmap for Clinical Implementation
  • From Stabilization to Depletion: Molecular Imaging to Measure Therapeutic Response in ATTR-CA
Show more Hot Topics

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire